Table 3

Adverse effects.

No. of trials

Chlorpromazine

Placebo

RR (95% CI) Random


events/total participants


General symptoms

Sedation

18

224/725

68/517

2.30 (1.7–3.1)

Weight gain > 10 lb; 4.5 Kg

5

31/75

7/90

4.44 (2.1–9.3)

Extrapyramidal symptoms

Acute dystonia

4

28/472

5/306

3.10 (1.3–7.7)

Parkinsonism

12

123/723

40/542

2.60 (1.2–5.4)

Fits

3

19/450

4/245

2.41 (0.4–16.4)

Akathisia

8

53/602

40/400

0.95 (0.5–1.9)

Allergic-type symptoms

Agranulocytosis/leucopenia

7

10/207

2/187

2.02 (0.7–5.6)

Rashes/itching

11

42/658

21/475

1.43 (0.9–2.4)

Jaundice

3

8/116

1/115

4.04 (0.9–17.9)

Photosensitivity

6

81/496

9/303

5.19 (2.7–9.8)

Eye opacity

2

97/431

16/226

3.09 (1.9–5.1)

Anti-cholinergic/nor-adrenergic symptoms

Hypotension + dizziness

15

113/708

38/524

1.90 (1.4–2.7)

Constipation

9

40/590

16/365

1.68 (0.9–2.9)

Urinary retention

3

11/459

5/253

1.49 (0.5–4.3)

Dry mouth

5

32/473

4/283

4.00 (1.6–9.8)

Blurred vision

6

10/529

9/381

1.10 (0.5–2.9)


Adams et al. BMC Medicine 2005 3:15   doi:10.1186/1741-7015-3-15

Open Data